Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
Tiziano Barbui, Alessandra Carobbio, Valerio De Stefano, Alberto Álvarez‐Larrán, Arianna Ghirardi, Greta Carioli, Francesca Fenili, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Laura Calabresi, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Francesca Gesullo, Silvia Betti, Francesco Ramundo, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Daniele Cattaneo, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi, Alessandro M. Vannucchi
Topics & Concepts
PhlebotomyMedicineTolerabilityClinical endpointPolycythemia veraInternal medicineAdverse effectHematologyBloodlettingSurrogate endpointHematocritDrugRandomized controlled trialSurgeryPharmacologyPathologyAlternative medicineMyeloproliferative Neoplasms: Diagnosis and TreatmentEosinophilic Disorders and SyndromesHemoglobinopathies and Related Disorders